Clinical Trial Update: PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a PD-1 inhibitor in combination with neoadjuvant chemoradiotherapy and surgery for locally advanced esophageal squamous cell carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Squamous Cell Esophageal Carcinoma, Esophageal Cancer | Phase 3 | Status: RECRUITING